Home > Neurology > ECTRIMS 2021 > Biomarkers > MRI more sensitive for disease activity than relapses in SPMS

MRI more sensitive for disease activity than relapses in SPMS

Presented By
Prof. Gavin Giovannoni, Queen Mary University of London, UK
Conference
ECTRIMS 2021
Trial
Phase 3, EXPAND
In both real-world and clinical trial setting, MRI activity was found to be a more sensitive tool to measure disease activity than relapses in secondary progressive MS (SPMS). Thus, the frequency of MRI monitoring is driving detection of disease activity. Even after 2 years without relapse and no MRI activity at baseline, disease activity returned in >50% of patients with previously ‘non-active’ MS on placebo [1]. Patients with SPMS are often categorised as active (aSPMS) or non-active (naSPMS) based on evidence of their disease activity, explained Prof. Gavin Giovannoni (Queen Mary University of London, UK). However, the relative contribution of MRI activity and/or relapses in defining disease activity is not well understood. Therefore, differences between aSPMS and naSPMS were evaluated. Data was used from the Adelphi real-world MS Disease Specific Programme (Adelphi MS DSP), and the phase 3 EXPAND study (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on